MedTech Resources

Company

Sonorous

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.

Private

Total raised (reported)

$1.5M

1 Form D offering, 2022 to 2022

Equity

$1.5M

Stock sold for cash

Debt and convertible notes

$0

Loans and notes sold to investors

Last known valuation

Unknown

Form D filings do not report valuation

Latest round: equity, $1.5M raised of $1.5M sought, first sale Jan 15, 2022, 14 investors.

Funding rounds (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
Jan 15, 2022Equity$1.5M$1.5M14Rule 506(b)Form D ↗Mar 7, 2022

Company details

From the company's latest Form D.

Legal name
Sonorous NV, Inc.
Headquarters
Lake Forest, California
Incorporated
Delaware in 2021
Entity type
Corporation
Revenue range
Decline to Disclose
Industry filed under
Other Health Care

Executives, directors and promoters

As listed on the latest Form D.

  • Dave FerreraExecutive Officer, Director
  • Charles YangExecutive Officer, Director
  • Randall TakahashiExecutive Officer, Director

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

No 5%+ shareholder filings or SBIR grants found under the name Sonorous.

Latest FDA decisions

Search the Clearance Tracker

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar

Reports received

0

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

0

Injury reports

0

Death reports

0

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor

No reports to chart for this view.

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

No device types to rank.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

No brand names to rank.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recalls under this name in FDA's data.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.